BOLGER JOHN C
Known title: DirectorCIK: 0001183863
Associated companies
Transaction History
| FLGT | ▲ Buy | Grant | 1,600 | $0 | 8/1/2022 | View on chart |
| FLGT | ▲ Buy | Option Exercise | 313 | $2K | 5/31/2022 | View on chart |
| FLGT | ▼ Sell | Open Market | 313 | $17K | 5/31/2022 | View on chart |
| FLGT | ▼ Sell | Open Market | 500 | $28K | 5/31/2022 | View on chart |
| FLGT | ▲ Buy | Option Exercise | 313 | $1K | 5/31/2022 | View on chart |
| FLGT | ▼ Sell | Open Market | 313 | $17K | 5/31/2022 | View on chart |
| FLGT | ▲ Buy | Grant | 2,000 | $0 | 5/18/2022 | View on chart |
| FLGT | ▼ Sell | Open Market | 625 | $38K | 3/1/2022 | View on chart |
| FLGT | ▲ Buy | Option Exercise | 625 | $2K | 3/1/2022 | View on chart |
| FLGT | ▼ Sell | Open Market | 625 | $38K | 3/1/2022 | View on chart |
| FLGT | ▲ Buy | Option Exercise | 625 | $4K | 3/1/2022 | View on chart |
| FLGT | ▼ Sell | Open Market | 625 | $38K | 3/1/2022 | View on chart |
| FLGT | ▲ Buy | Option Exercise | 625 | $10K | 3/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
FLGT compared to PRPO in cancer diagnostics sector
A recent article compares Fulgent Genetics with PrecisionDx, evaluating which cancer diagnostics stock has more potential. This comparison highlights FLGT's position within the specialized diagnostics market. The stock is currently trading near the average analyst target price of $19.00, which sits within its 52-week range.
FLGT compared to PRPO in cancer diagnostics sector. A recent article compares Fulgent Genetics with PrecisionDx, evaluating which cancer diagnostics stock has more potential. This comparison highlights FLGT's position within the specialized diagnostics market. The stock is currently trading near the average analyst target price of $19.00, which sits within its 52-week range.